Efficacy with Trastuzumab Deruxtecan for Non-Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutation in a Patient with a Poor Performance Status: A Case Report

Antibody–drug conjugate (ADC) was novel type of anticancer drugs. Trastuzumab deruxtecan (T-DXd), a human epidermal growth factor receptor 2 (HER2) targeting ADC, can be a novel treatment option for HER2 alternation (mutation, expression, amplification) advanced-stage non-small-cell lung cancer (NSC...

Descripción completa

Detalles Bibliográficos
Autores principales: Kato, Yuki, Kato, Yasuhiro, Minegishi, Yuji, Suzuki, Takahiro, Nakamichi, Shinji, Matsumoto, Masaru, Miyanaga, Akihiko, Noro, Rintaro, Kubota, Kaoru, Terasaki, Yasuhiro, Seike, Masahiro, Gemma, Akihiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8627308/
https://www.ncbi.nlm.nih.gov/pubmed/34848974
http://dx.doi.org/10.2147/OTT.S341290

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8627308/
https://www.ncbi.nlm.nih.gov/pubmed/34848974
http://dx.doi.org/10.2147/OTT.S341290

Ejemplares similares